SMART STUDY DESIGNS FOR STRATEGIC CLINICAL TRIALS

Abemaciclib with endocrine therapy ± paclitaxel in aggressive ER+/HER2- advanced breast cancer

Bevacizumab plus chemotherapy in locally recurrent or metastatic breast cancer

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ metastatic breast cancer

Prospective evaluation of microbiome as a potential predictive factor for immunotherapy in luminal-like breast cancer within the KELLY clinical study

Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB HR+, HER2- Breast Cancer

Pembrolizumab and eribulin for HR+/HER- metastatic breast cancer previously treated with antracyclines and taxanes

First Line Eribulin monotherapy In HER2- Metastatic Breast Cancer

A Two-stage Simon Design Phase II Study of Single Agent Olaparib for Non-BRCA MBC Patients With HRD

Palbociclib with second-line endocrine therapy for HR+/HER2- Advanced Breast Cancer patients who had a clinical benefit during first-line palbociclib-based...

Phase II study of the combination of Pembrolizumab and Lenvatinib in pre-treated thymic carcinoma

Identification of endometrial cacinoma biomarkers associated with a short term exposure to temsirolimus

PQR309 and eribulin for locally advanced or metastatic HER- and TNBC

Real-World Data of Clinicopathological Characteristics and Management of Patients With HER2+ Breast Cancer

Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer (TELESCOPE)

Partritumab deruxtecan in patients with active brain mets from mBC and NCSLC, and leptomeningeal carcinomatosis from advanced solid tumors

Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer

Elacestrant + everolimus in patients with ER+/HER2-, esr1mut, advanced breast cancer progressing on endocrine therapy and CDK4/6 inhibitors

First-line atezolizumab with paclitaxel and bevacizumab for advanced or metastatic TNBC

Durvalumab and chemotherapy induction followed by durvalumab and radiotherapy in large volume stage III NSCLC

Tocilizumab with pembrolizumab for treatment of COVID-19 pneumonia in patients unresponsive to standard care

Giredestrant (GDC-9545) or Tamoxifen in ER+/HER2- Ki67≥10% Early Breast Cancer

Sub-study of predictive immunogenicity biomakers for target therapy in HER2+ early breast cancer

Metformin to prevent hyperglycemia in HR+/HER- PI3KCA-mutated advanced breast cancer patients treated with alpelisib and endocrine therapy

Neoadjuvant therapy with weekly (1) paclitaxel and neratinib, or (2) trastuzumab and paclitaxel, or (3) neratinib, trastuzumab, and paclitaxel, followed by...

Palbociclib with fulvestrant or letrozole for HER-, ER+ metastatic breast cancer

Nal-iri for progressing brain mets in patients with HER2- breast cancer

Biomarker changes associated to short exposure to olaparib as potential predictors in Endometrial Carcinoma

Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-Negative Breast Cancer

MEN1611 monotherapy or in combination with eribulin for PIK3CA/PTEN altered metaplastic breast cancer

Trastuzumab emtansine (TDM1) with non pegylated liposomal doxorubicin in HER2+ metastic breast cancer

Trastuzumab-deruxtecan in HER2-low breast cancer with newly diagnosed or progressing brain metastases

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (ANALLISA)

Osimertinib in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ metastatic breast cancer

Trastuzumab deruxtecan in HER2+ advance breast cancer with brain mets and/or leptomeningeal carcinomatosis

Evaluation of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status

Lurbinectedin with Pembrolizumab in relaspsed small cell lung cancer

Monitoring Minimal Residual Disease Using ctDNA in HR+/HER2- early breast cancer

Olaparib plus Trastuzumab for HER2+, BRCA Mutated or HRD Advanced Breast Cancer

Palbociclib with fulvestrant or letrozole for HER-, ER+ metastatic breast cancer

Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: A FDG-PET response-adapted strategy

Optimization of balixafortide with nab-paclitaxel or eribulin for HER2- advanced breast cancer

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

Spanish Lung Liquid vs. Invasive biopsy Program

Sub-study of predictive biomarkers for palbociclib and endocrine therapy in ER+/HER2- advanced breast cancer

Datopotamab Deruxtecan in Non-Squamous Non-Small Cell Lung Cancer patients with active Brain Metastases

Open label trial of Asunercept for severe COVID-19 disease

Evaluation of ipatasertib added to combination of neoadjuvant chemotherapy and atezolizumab in women with TNBC

CB-103 plus NSAI and letrozole or anastrozole in luminal advanced breast cancer

Subcutaneous trastuzumab and pertuzumab Maintenance after T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherapy

Niraparib plus Aromatase Inhibitors for Luminal-like and gBRCA or HRD-positive Metastatic Breast Cancer

Evaluation of an artificial intelligence system in the extraction of data from electronic health records compared to data obtained through traditional.

Phase II Study of the Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma

Ipatasertib with non-taxane chemotherapy for taxane-pretreated unresectable locally advanced or metastatic TNBC

Trastuzumab, pertuzumab and TDM1 for HER2+ early breast cancer

T-DXD vs. CDK4/​6-Inhibitor Based endocrine therapy as first-line therapy of HR-positive and HER2-low/​ultralow advanced breast cancer patients classified as non-luminal subtype (PONTIAC)

Eribulin monotherapy or eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy

Spanish lung liquid vs. invasive biopsy program evaluation.

Clinical benefit of trastuzumab with lapatinib in HER2+ breast cancer previously treated with trastuzumab and/or lapatinib

Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/​HER2- Advanced Breast Cancer (WIN-B)